Skinvisible will take further steps into the skin care field after launching a new wholly-owned subsidiary called Kintari that will market a premium line of products powered by the company's patented Invisicare technology.
As part of the company's strategic focus on revenue generation and creating shareholder value, Kintari will be a direct sales company that will launch products initially in the United States and Canada.
"Investment in our new subsidiary Kintari reflects Skinvisible's ongoing commitment to maximize value for our shareholders," says Terry Howlett, CEO of Skinvisible.
"We have ambitious plans for many products. Our R&D pipeline consists of over thirty cosmeceutical and over-the-counter formulations which are available for Kintari to market. Our plan is to leverage the direct sales model to tell the Invisicare story which is the foundation of all our great products."
The Skinvisible chief adds that a fourth quarter launch is planned in the United States and Canada and will be expected to generate revnue then.
Traditionally a company with a strong background in pharmaceuticals, Skinvisible’s Kintari product portfolio will consist of a range of anti-aging creams developed using proven ingredients with scientific evidence of their effectiveness at reducing the look of fine lines and wrinkles resulting in youthful looking skin.
It is also expected that additional products will be added to enhance this product line as the company grows and expands.
Skinvisible explains it has selected the direct sales model for Kintari products as it enables the company to reach consumers directly and effectively with products formulated with the benefits of Invisicare.
Invisicare is a patented polymer delivery system that enhances the delivery of active ingredients for topically applied skin care products.
Its patented technology has a unique formula and process for combining active ingredients with a delivery system that extends the duration of time the product remains on the skin and active.
In line with Skinvisible's direct sales strategy, Skinvisible Pharmaceuticals Inc. will continue to build its patent portfolio and its core business of R&D and licensing our prescription product line focused on dermatology conditions.